The FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor in combination with Roche’s Tecentriq for the treatment of metastatic colorectal cancer.
- Home |
- FDA delays approval decision for Exelixis’ tyrosine kinase inhibitor in colorectal cancer
FDA delays approval decision for Exelixis’ tyrosine kinase inhibitor in colorectal cancer
- September 11, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
